Clinical trials: Cognitive Impairment
Parkinson's Disease With Cognitive Impairments
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
The purpose of this research trial is to determine if safinamide (experimental drug) can improve cognition in cognitively impaired but non-demented Parkinson's disease patients.
- Trial name
- NCT01211587
- Testing
- safinamide
- Where
- 15 sites in United States, Spain
- Volunteers
- 103 people
- Sponsor
- Newron Pharmaceuticals SPA
Cognitive Decline, Focus Deficit
Effects of Auri Super Mushroom Daily Gummies on Cognitive Health
This is a single-arm, open-label, virtual clinical trial evaluating the cognitive health effects of Auri Super Mushroom Daily Gummies in a population of 35 adult participants over 8 weeks.
- Trial name
- NCT07198399
- Testing
- Auri Super Mushroom Daily Gummies
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Auri Nutrition
Cognitive Dysfunction
Flutemetamol F 18 Injection Formulation Comparison
VIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other…
- Trial name
- NCT07873463
- Testing
- GE-287, Vizamyl
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- GE Healthcare
Schizophrenia
A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder
This randomized, double-blind, placebo-controlled parallel group study will assess the effect on biomarkers measures of cognitive dysfunction, the clinical efficacy and safety of RO4917838 in participants with schizophrenia and…
- Trial name
- NCT01116830
- Testing
- RO4917838, Standard Antipsychotic Therapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Mild Cognitive Impairment, So Stated
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
- Trial name
- NCT00422981
- Testing
- AL-108
- Where
- 17 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Allon Therapeutics
Schizophrenia
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
To assess if PF-04958242 can attenuate the ketamine-induced cognitive impairment in verbal learning and memory, episodic memory and spatial working memory in healthy volunteers.
- Trial name
- NCT01749098
- Testing
- PF-04958242, Ketamine
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Biogen
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once per day for up to 12 weeks to patients with mild cognitive impairment.
- Trial name
- CT04 (NCT01303744)
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 9 sites in United States, Italy
- Volunteers
- 96 people
- Sponsor
- CERESPIR
Engagement, Patient, Mood
SimpleC Wellness Platform With Social Robot Interaction
This implementation study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Mood, Quality of Life, Aging
- Trial name
- NCT05296239
- Testing
- SimpleC Wellness Platform with Social Robot Interaction
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- SimpleC, LLC
Alzheimer's Disease
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565382
- Testing
- florbetapir F 18
- Volunteers
- 40 people
- Sponsor
- Avid Radiopharmaceuticals
Cognitive Dysfunction
Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major Surgery
Postoperative cognitive impairment develops in the early and continues in the late postoperative period; it is manifested by impaired memory, attention, concentration and other higher cortical functions (thinking, speech).
- Trial name
- NCT03849664
- Testing
- Cytoflavin® solution, Cytoflavin® enteric-coated tablet
- Where
- 13 sites in Russia
- Volunteers
- 200 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Schizophrenia
Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen
- Trial name
- NCT04972227
- Testing
- CY6463
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Tisento Therapeutics
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled and multiple dose escalation phase Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in patients with Alzheimer's…
- Trial name
- NCT06619613
- Testing
- Alzheimer Disease (AD)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Keymed Biosciences Co.Ltd
Ischemic Stroke Hospitalized, Impairment, Cognitive
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood…
- Trial name
- GiCIIS (NCT07220538)
- Testing
- Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.), Standard of care (SoC) Group
- Where
- 34 sites in China
- Volunteers
- 400 people
- Sponsor
- Dr. Willmar Schwabe GmbH & Co. KG
Vascular Cognitive Impairment no Dementia
Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults
The primary objective of this study is to evaluate the efficacy of Mexidol® sequential parenteral and oral administration as part of comprehensive therapy in older adults with chronic brain ischemia and vascular cognitive…
- Trial name
- NCT07700615
- Testing
- Mexidol, Standard Therapy
- Where
- 4 sites in Russia
- Volunteers
- 120 people
- Sponsor
- Pharmasoft
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.
This study in young and elderly healthy subjects will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01181934
- Testing
- A643 (nicotine)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Cognitive Dysfunction, Cognitive Impairment
CAMCI: Advancing the Use of Computerized Screening in Healthcare
Cognitive impairment is a significant health problem in the United States, resulting in costs over $100 billion a year. We will provide an efficient, effective, and financially intelligent solution to Primary Care Physician's to…
- Conditions
- Cognitive Dysfunction, Cognitive Impairment, Cognitive Decline, Cognitive Change
- Trial name
- NCT03512301
- Testing
- CAMCI, MoCA, Clinical Adjudication
- Where
- 4 sites in United States
- Volunteers
- 773 people, healthy volunteers welcome
- Sponsor
- Psychology Software Tools, Inc.
Healthy, Cognitive Impairment
Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology
The study is designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical assessments and BNA scores.
- Conditions
- Healthy, Cognitive Impairment, Neurological Disorder
- Trial name
- NCT03699514
- Testing
- Brain Network Activation (BNA™) technology
- Where
- 4 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd